NASDAQ: KROSKeros Therapeutics Inc Stock Ownership - Who owns Keros Therapeutics?
Insider buying vs selling
Have Keros Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Jean Jacques Bienaime | Director | 2026-03-09 | 2,000 | $11.21 | $22.42kBuy |
| Jasbir Seehra | CHIEF EXECUTIVE OFFICER | 2026-02-19 | 7,015 | $16.17 | $113.43kSell |
| Keith Regnante | CHIEF FINANCIAL OFFICER | 2026-02-18 | 4,739 | $16.35 | $77.48kSell |
| Lorena Raquel Lerner | Chief Science Officer | 2026-02-18 | 3,873 | $16.35 | $63.32kSell |
| Esther Cho | SVP General Counsel | 2026-02-18 | 4,745 | $16.35 | $77.58kSell |
| Carl L. Gordon | Director | 2025-11-21 | 140,057 | $17.75 | $2.49MSell |
| Carl L. Gordon | Director | 2025-11-21 | 74,465 | $17.75 | $1.32MSell |
| Julius Knowles | Director | 2025-11-21 | 191,527 | $17.75 | $3.40MSell |
| Julius Knowles | Director | 2025-11-21 | 130,494 | $17.75 | $2.32MSell |
| Orbimed Advisors LLC | Director | 2025-11-21 | 140,057 | $17.75 | $2.49MSell |
KROS insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when KROS insiders and whales buy or sell their stock.
KROS Shareholders
What type of owners hold Keros Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Blackrock Inc | 11.62% | 2,290,532 | $25.38M | Institution |
| Alon Lazarus | 10.33% | 2,036,140 | $22.56M | Insider |
| Arkin Bio Ventures Limited Partnership | 10.21% | 2,013,102 | $22.31M | Insider |
| Vanguard Group Inc | 7.74% | 1,525,355 | $16.90M | Institution |
| Arrowstreet Capital Limited Partnership | 6.77% | 1,334,516 | $14.79M | Institution |
| Pontifax Management 4 GP 2015 Ltd | 6.27% | 1,236,912 | $13.70M | Insider |
| Carl L. Gordon | 5.93% | 1,170,119 | $12.96M | Insider |
| Orbimed Advisors LLC | 5.91% | 1,164,869 | $12.91M | Insider |
| State Street Corp | 5.46% | 1,075,993 | $11.92M | Institution |
| Madison Avenue Partners LP | 4.18% | 823,707 | $9.13M | Institution |
KROS vs Biotech Stocks
Keros Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.